Coherus Content With Dual Pipeline Strategy
US Firm Reveals Full-Year Udenyca Biosimilar Sales
Coherus BioSciences sees value in having both wholly-owned and in-licensed biosimilar assets, as the firm gears up to have a portfolio of at least six products within five years.
You may also be interested in...
In the third and final part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies, one or two new entrants appeared towards the bottom of the top 50.
Bausch + Lomb has struck a deal for US and Canadian rights to the Xlucane ranibizumab biosimilar rival to Lucentis that is being developed by Xbrane Biopharma and Stada.
Coherus BioSciences plans to dip into the financing market once again in order to fuel its operations, which include several biosimilar candidates in late-stage clinical development. However, at the same time, the firm has acknowledged the damage the accelerating COVID-19 crisis could have on operations, if only for a short while.